LSD-Assisted Psychotherapy for Generalized Anxiety Disorder

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for an effective treatment for generalized anxiety disorder that is not associated with life-threatening somatic illnesses, as current pharmacological and psychotherapeutic options are limited in efficacy and are often accompanied by adverse effects.

Innovation Solution

Administering a psychedelic, preferably LSD, to individuals with generalized anxiety disorder to induce a psychedelic state and assist psychotherapy, thereby reducing anxiety and depression rating scale scores and general psychological distress for several weeks beyond the administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional pharmacological treatments are used for generalized anxiety disorder, then anxiety symptoms can be managed, but adverse effects occur and efficacy is limited

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidadverse effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the pharmacological parameter by using psychedelic substances (LSD, psilocybin, DMT) instead of conventional anxiety medications. These psychedelics act on serotonin 5-HT2A receptors to produce acute therapeutic effects that reduce anxiety and depression symptoms without the adverse effects associated with conventional treatments, while maintaining therapeutic efficacy through controlled administration protocols

Inventive Principle:

Principle #35Parameter changes

2Reliability

If conventional psychotherapy is used for generalized anxiety disorder, then therapeutic benefits can be achieved, but the treatment process is time-consuming and limited in efficacy

Engineering Contradiction:

Improvetherapeutic benefitsVSAvoidtreatment duration

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by administering psychedelic substances before and during critical psychotherapy sessions. The psychedelics prepare the patient's mind by inducing altered states of consciousness, enhancing introspection, and reducing defensive barriers, which allows therapy to be more effective and shorter in duration compared to conventional psychotherapy alone

Inventive Principle:

Principle #10Preliminary action

3Reliability

If psychedelic substances are administered to induce therapeutic effects, then anxiety and depression ratings are significantly reduced, but the substance induces altered states of consciousness

Engineering Contradiction:

Improvereduction in anxiety and depression ratingsVSAvoidaltered states of consciousness

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the potentially harmful altered states of consciousness induced by psychedelics into beneficial therapeutic effects. By controlling the administration setting, dosage, and combining it with structured psychotherapy, the altered states are harnessed to enhance introspection, reduce anxiety and depression, and facilitate lasting therapeutic change, thereby transforming what could be considered harmful into highly beneficial outcomes

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of LSD in this method significantly reduces state-trait anxiety inventory ratings, Hamilton Depression Rating Scale scores, and Symptom-Check-List-90 ratings, indicating effective short-term and long-term therapeutic benefits for patients with generalized anxiety disorder.

Implementation Method 1

All serotonergic psychedelics including LSD, psilocybin, DMT, and mescaline are agonists at the 5-HT2A receptor (Rickli et al., 2016) and may therefore produce overall largely similar effects. Additionally, psychedelic substances produce their acute effects in humans via activation of the serotonin 5-HT2A receptor

Methodology Applied

Scientific EffectReceptor activation:

Data Source

PatentUS20250152565A1Effects of lysergic acid diethylamide (LSD) and of LSD analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness

Publication Date: 2025.05.15 UNIVSSPITAL BASEL

AI summary

A method of treating anxiety disorders specifically not associated with causes such as a life-threatening serious somatic illness, by administering a psychedelic to an individual, and treating anxiety and specifically causing reductions in the rating scale score measures of anxiety (STAI global or state or trait anxiety) and/or measures of depression (HDRS or BDI scores) and/or measures of general psychological distress (SCL-90 ratings) in the patient for several weeks beyond administration of the psychedelic. A method of treating anxiety, by administering a psychedelic (preferably LSD) to an individual having anxiety not associated with causes such as a life-threatening serious somatic illness, and inducing positive acute drug effects and positive long-term therapeutic effects in the individual.